Status | Study |
Terminated |
Study Name: Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2011-04-12 Interventions: Drug: ALXN1102 Single Ascendin |
Completed |
Study Name: Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Condition: Hemoglobinuria, Paroxysmal Date: 2010-10-18 |
Completed |
Study Name: E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Condition: Paroxysmal Nocturnal Hemoglobinuria Date: 2010-08-30 Interventions: Drug: Eculizumab Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 da |
Completed |
Study Name: C07-001: Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Condition: Paroxysmal Nocturnal Hemoglobinuria Date: 2010-08-30 Interventions: Biological: Eculizumab Subjects were treated with open label Eculizumab and following the dose described |
Completed |
Study Name: Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes Condition: Hemoglobinuria Date: 2010-08-30 |
Completed |
Study Name: Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria Condition: Paroxysmal Nocturnal Haemoglobinuria Date: 2009-11-20 |
Completed |
Study Name: Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Condition: Hemoglobinuria, Paroxysmal Date: 2009-03-23 Interventions: Drug: Eculizumab Other Name: Soliris |
Completed |
Study Name: The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Hemoglobinuria, Paroxysmal Date: 2008-07-23 |
Approved for marketing |
Study Name: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Condition: Hemoglobinuria, Paroxysmal Date: 2007-02-20 Interventions: Drug: eculizumab 600mg IV every week and 900mg IV every 2 weeks |
Completed |
Study Name: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Hemoglobinuria, Nocturnal Date: 2005-07-20 Interventions: Drug: eculizumab 600 mg intrav |